Background: We investigated osteoporosis management strategies and clinical outcomes following the occurrence of medicationrelated osteonecrosis of the jaw (MRONJ). Methods: We retrospectively studied individuals diagnosed with MRONJ during osteoporosis treatment who were managed in the Osteoporosis Center or the Oral Maxillofacial Surgery & Dental Unit at Queen Mary Hospital in Hong Kong between 2010 and 2022. We examined subsequent osteoporosis management plans, fracture events, and bone mineral density (BMD). Results: Thirty-six individuals were included (mean age, 78.5 years; 94.4% women). The estimated prevalence of MRONJ was 0.26%. All patients had been exposed to bisphosphonates, and seven had also received denosumab before MRONJ. Following MRONJ, only 14 individuals continued anti-osteoporosis treatment, a decision influenced by a higher fracture probability at MRONJ onset. The most common regimen was a teriparatide-raloxifene sequence (n=8): three patients achieved stable BMD, four achieved improving BMD, and one exhibited a mixed response. The patient with a mixed BMD response had also been treated with denosumab. Six patients sustained incident fractures after MRONJ, and these patients had lower BMD T-scores than their counterparts. Two patients experienced MRONJ recurrence, which was associated with the resumption of bisphosphonate or denosumab therapy after MRONJ. These patients had higher BMD T-scores than those who did not experience MRONJ recurrence. Conclusion MRONJ is challenging because high fracture risk necessitates discontinuation of antiresorptive agents. Teriparatide followed by raloxifene may be a reasonable regimen. Individualised decisions in osteoporosis management after MRONJ are required to balance fracture risk reduction with minimising MRONJ recurrence.

Objective To explore the concentration of serum placental alkaline phosphatase in cervical cancer patients and its potential clinical application value.Methods Fifty-three cervical cancer patients who received treatment in Department of Gynaecology and Obstetrics,the First Hospital of Nanchang from January 2023 to February 2024 were selected retrospectively as cervical cancer group,and fifty-three women who underwent physical examination were selected as health control group during the same period.The concentration of serum placental alkaline phosphatase levels and serum total alkaline phosphatase activity between two groups above were detected and compared.Results The level of serum placental alkaline phosphatase of patients in cervical cancer group were higher than that in health control group(t=53.461,P<0.001),and the activity of serum total alkaline phosphatase was lower than that in health control group(t=9.910,P<0.001).Conclusion The elevated levels of serum placental alkaline phosphatase in cervical cancer patients may be related to their condition.

Objective To explore the concentration of serum placental alkaline phosphatase in cervical cancer patients and its potential clinical application value.Methods Fifty-three cervical cancer patients who received treatment in Department of Gynaecology and Obstetrics,the First Hospital of Nanchang from January 2023 to February 2024 were selected retrospectively as cervical cancer group,and fifty-three women who underwent physical examination were selected as health control group during the same period.The concentration of serum placental alkaline phosphatase levels and serum total alkaline phosphatase activity between two groups above were detected and compared.Results The level of serum placental alkaline phosphatase of patients in cervical cancer group were higher than that in health control group(t=53.461,P<0.001),and the activity of serum total alkaline phosphatase was lower than that in health control group(t=9.910,P<0.001).Conclusion The elevated levels of serum placental alkaline phosphatase in cervical cancer patients may be related to their condition.